Bide Pharmatech Co., Ltd.

SHSE:688073 Stock Report

Market Cap: CN¥3.1b

Bide Pharmatech Past Earnings Performance

Past criteria checks 2/6

Bide Pharmatech has been growing earnings at an average annual rate of 27.1%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 21.2% per year. Bide Pharmatech's return on equity is 4.8%, and it has net margins of 9%.

Key information

27.1%

Earnings growth rate

24.2%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate21.2%
Return on equity4.8%
Net Margin9.0%
Last Earnings Update31 Mar 2024

Recent past performance updates

There May Be Reason For Hope In Bide Pharmatech's (SHSE:688073) Disappointing Earnings

May 02
There May Be Reason For Hope In Bide Pharmatech's (SHSE:688073) Disappointing Earnings

Recent updates

There May Be Reason For Hope In Bide Pharmatech's (SHSE:688073) Disappointing Earnings

May 02
There May Be Reason For Hope In Bide Pharmatech's (SHSE:688073) Disappointing Earnings

Revenue & Expenses Breakdown
Beta

How Bide Pharmatech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688073 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 241,1029926159
31 Dec 231,09211025460
30 Sep 231,05016121752
30 Jun 2398817119651
31 Mar 2390915718250
31 Dec 2283414617143
30 Sep 2276812916539
30 Jun 2270711416534
31 Mar 2264910115534
31 Dec 216069814832
31 Dec 203915910818
31 Dec 19249-111122
31 Dec 18163-199013

Quality Earnings: 688073 has high quality earnings.

Growing Profit Margin: 688073's current net profit margins (9%) are lower than last year (17.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688073 has become profitable over the past 5 years, growing earnings by 27.1% per year.

Accelerating Growth: 688073's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 688073 had negative earnings growth (-37.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.1%).


Return on Equity

High ROE: 688073's Return on Equity (4.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.